Patients who are homozygous for the G to A nontranslated prothrombin polymorphism only occasionally have venous thrombosis. An evaluation of all published papers on the subjects has disclosed that nine patients of the 35 so far reported remained asymptomatic in spite of the presence of associated congenital or acquired thrombotic risk factors. We saw an additional patient recently, bringing the total to 10 of 36 patients. Some of these patients remained asymptomatic in spite of multiple or repetitive risk factors (e.g., five pregnancies in the case of one patient). Twelve patients who were homozygous and who had this polymorphism developed symptoms only in the presence of the same risk factors. This may suggest that this abnormality played a small role, if in both groups of patients. The finding that several patients with this abnormality remained asymptomatic in spite of associated risk factors casts serious doubts about the prothrombotic significance of this polymorphism. Until this problem is clarified, the Clinician must abstain from attributing a prothrombotic effect to this polymorphism.
Summary: Patients who are homozygous for the G to A nontranslated prothrombin polymorphism only occasionally have venous thrombosis. An evaluation of all published papers on the subjects has disclosed that nine patients of the 35 so far reported remained asymptomatic in spite of the presence of associated congenital or acquired thrombotic risk factors. We saw an additional patient recently, bringing the total to 10 of 36 patients. Some of these patients remained asymptomatic in spite of multiple or repetitive risk factors (e.g., five pregnancies in the case of one patient). Twelve patients who were homozygous and who had this polymorphism developed symptoms only in the presence of the same risk factors. This may suggest that this abnormality played a small role, if in both groups of patients. The finding that several patients with this abnormality remained asymptomatic in spite of associated risk factors casts serious doubts about the prothrombotic significance of this polymorphism. Until this problem is clarified, the Clinician must abstain from attributing a prothrombotic effect to this polymorphism. Key Words: Congenital thrombophilia-Hypercoagulability-Polymorphisms-Prothrombin-Thrombosis, A G to A polymorphism in the nontranslated region of the prothrombin gene has been maintained recently to be associated with venous thromboembolism (1). So far, data supporting this association have been obtained only from the observation that a higher prevalence of this polymorphism occurred in patients with venous thrombosis, compared with control subjects (2,3).
The observation that many homozygous patients with this polymorphism may remain asymptomatic has cast doubts on the significance of this abnormality in the pathogenesis of venous thromboembolism (4-7). A care-fuI evaluation of the literature, together with personal experience, also has allowed us to focus the attention on the fact that, in several instances, these patients who are homozygous remained asymptomatic in spite of the presence of associated congenital or acquired risk factors. This observation prompted this report.
MATERIALS AND METHODS
All available articles dealing with the nontranslated 20210 G to A prothrombin polymorphism have been examined by two independent investigators. All articles I i that reported homozygote patients were selected and . 1 ' thoroughly evaluated. Heterozygous patients were not taken into consideration. Genetic analysis was compared I with family pedigree, when available. For the purposes I of this study, the authors took into consideration only deep vein thrombosis (DVT) or pulmonary embolism (PE). m~tic c~r ~~ ~ I Patients were allocated to the symptomatic or asymptomatic groups according to the above-mentioned findings. The authors then sought the existence of associated congenital or acquired risk factors in both groups of patients. Acquired associated conditions (surgery, pregnancy, immobilization, old age) were maintained as such only if concomitant with the thrombotic episode; these were recorded. All patients who became symptomatic only during the above-mentioned associated risk factors were listed. The authors also selected those patients who remained asymptomatic in spite of the presence of congenital or acquired conditions.
RESULTS

'
The literature currently reports on nine homozygous patients with this prothrombin abnormality, of a total 1 35 patients so far reported (4-11) who remained asymp-j tomatic in spite of associated risk factors. We recently saw one additional patient, as yet unreported. This was a 50-year-old female who remained asymptomatic in spite of the presence of lupus anticoagulant. This latter obser-: vation therefore brings the total to 10 patients, of a total of 36 patients.
The main features of these patients are reported in Table I . Associated risk factors found were: old age (n = 3~; surgery (n =5); pregnancy (n = 5); cancer (n = 1); and diabetes (n .~ 1). In most instances, there was only one risk factor per patient. However, a few patients had two or three risk factors each. The patient presented by Alatri (4) showed both old age (> 65) and surgery (two procedures) without any specific prophylaxis, and remained asymptomatic. Of particular significance also is the case presented by Akar et al. (8). This patient, age 73, remained asymptomatic in spite of three well-known prothrombotic risks, namely, old age, diabetes, and cancer-an interesting observation indeed. In the family presented by Morange et al. (9), four of five of the subjects were asymptomatic. They remained so in spite of pregnancies and surgery. In one instance, the mother of five affected siblings (four homozygotes and one heterozygote), had no thrombosis in spite of five pregnancies-another important observation, if one takes into account the'fact that this patient was also homozygous for the methylenetetrahydrofolate reductase (MTHFR) defect.
The main features of patients who developed symptoms only in presence of associated congenital or acquired conditions are presented in Table 2 . Twelve patients were presented in this group. The most frequently found associated risks were heterozygous factor V Leiden, surgery, and pregnancy. Either one or more than one associated risk factors was present in the same patient.
DISCUSSION
This large number of patients who were homozygous and who had this abnormality, who remained asymptom-atic in spite of association risk factors, is striking. Altogether 10, of 36 patients remained asymptomatic in spite of associated risk factors {4~--IQ~, whereas 12 of 36 developed symptoms only when exposed to the same risk factors (1,9,12-18)&horbar;an even distribution that is inconsistent with the sure prothrombotic effects of this abnormality. This is of particular importance when one also takes into account the fact that only five of 36 patients so far reported showed what appeared to be idiopathic deep vein thrombosis (DVT). This is not intended to minimize the effect of associated (acquired or congenital) risk factors as contributing elements in the triggering of venous thrombosis: quite the contrary. A recent study of a family with combined homozygous 20210 prothrombin abnormality and heterozygous factor V Leiden defect showed that patients became symptomatic only when acquired additional factors were present (16) . Acquired conditions always are very important, and often are not property appreciated (19) .
All these observations seem to indicate that the prothrombin abnormality is, by itself, a minor prothrombotic defect, if any. It could play a contributory role in given circumstances, e.g., association with factor V Leiden.
However, this also remains to be proven. The frequent finding of these two polymorphisms in the same person could only reflect their relatively high prevalence in the general population (2-4%).
Very important is the case of the 39-year-old woman whom we presented, who took oral contraceptives for several years without developing any thrombosis (5). It is worth mentioning that an increased prothrombin level has been maintained to be the mechanism whereby the abnormality plays a prothrombotic role. Because oral contraceptives have been demonstrated to increase the level of prothrombin complex factors, it is really surprising to see that no thrombosis developed. However it has to be noted that the increased prothrombin level is not always present in this prothrombin abnormality (20) . Needless to say, these observations are not intended to purport that the abnormality exercises a protective role against venous thrombosis. This is not the point. The problem is that these findings, nonetheless, weigh heavily against the role of this abnormality in the pathogenesis of thrombosis. Because many claims are being circulated these days on the sole basis of association studies, it may be wiser to proceed with extreme caution before assigning a prothrombotic role to this defect. Even granting that a variably increased prothrombin level may be present thereby creating hypercoagulability, one has to remember that hypercoagulability does not necessarily mean thrombosis (21, 22) . Also, the fact that three patients reached the ages of 72, 73, and 74 years respectively without any thrombotic manifestations raises serious doubts about the prothrombotic effect of this abnormality.
The retrospective case-versus-control studies indicating the presence of a relationship between the abnormality and an increased prevalence of thrombosis are not fully satisfactory (23, 24) . This difference may be caused by biased selection of the control population (population stratification) or by incomplete or biased statistical evaluation (24) . Furthermore, the existence of an association between two phenomena does not necessarily indicate that a causal relationship exists between the two (24, 25) . In this regard, it is worth remembering that none of the papers dealing with the subject used corrective measures such as associated studies with internal control (ASIC), the haplotype relative risk (HRR), or the transdisequilibrium test (TDT) in an attempt to ctimiour reduce the bias (24) .
Only prospective studies could supply a definite answer to this problem. Such prospective studies should compare the incidence of thrombosis occurring during the follow-up in affected family members (excluding the propositi or propositae) in comparison with that seen in nonaffected family members. Similar studies have been carried out recently for factor V Leiden; these have discovered that even that defect is not as important as originally thought (26) . 1 In conclusion, it is advisable to abstain, for the present time, from any claim regarding the prothrombotic role off this abnormality (2, 3, 27) . On the basis of available data, it is also likely that the screening for this abnormality is / not indicated in patients affected by venous thrombosis. / Already strained national health systems or health insurances can hardly afford to pay for tests that may be of no benefit for the patient. 
